Literature DB >> 9453483

Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans.

J W Konturek1, A Dembinski, S J Konturek, J Stachura, W Domschke.   

Abstract

BACKGROUND & AIMS: Involvement of Helicobacter pylori in aspirin-induced gastropathy and adaptation to aspirin remains unclear. The aim of this study was to compare gastric damage and adaptation after repeated exposures to acetylsalicylic acid in the same subjects before and after eradication of H. pylori.
METHODS: Before and after H. pylori eradication, 8 volunteers were given aspirin, 2 g/day during 14 days. Mucosal damage was evaluated by endoscopy and histological analysis of biopsy samples. Gastric microbleeding, DNA synthesis, prostaglandin E2 generation, and luminal contents of transforming growth factor alpha and its immunohistochemical expression were determined on days 0, 3, 7, and 14 of aspirin course.
RESULTS: In all subjects, aspirin-induced gastric damage that reached maximum on day 3. In H. pylori-positive subjects, this damage was maintained at a similar level up to day 14. After H. pylori eradication, the damage was significantly lessened both in endoscopy and histology at day 14 and accompanied by increased mucosal expression and luminal release of transforming growth factor alpha. Prostaglandin E2 generation was significantly greater in H. pylori-positive subjects than after H. pylori eradication, but aspirin treatment resulted in >90% reduction of this generation independent of H. pylori status.
CONCLUSIONS: Gastric adaptation to aspirin is impaired in H. pylori-positive subjects, but eradication of this bacterium restores this process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453483     DOI: 10.1016/s0016-5085(98)70474-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.

Authors:  T I Kim; Y C Lee; K H Lee; J H Han; C Y Chon; Y M Moon; J K Kang; I S Park
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 3.  Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.

Authors:  R La Corte; M Caselli; G Castellino; G Bajocchi; F Trotta
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

4.  Effect of high-dose aspirin on Helicobacter pylori eradication.

Authors:  Seung Ha Park; Dong Il Park; Sang Hoon Kim; Hong Joo Kim; Yong Kyun Cho; In Kyung Sung; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Keuk Keum
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 5.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

7.  Helicobacter pylori infection potentiates aspirin induced gastric mucosal injury in Mongolian gerbils.

Authors:  N Yoshida; N Sugimoto; F Hirayama; Y Nakamura; H Ichikawa; Y Naito; T Yoshikawa
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

8.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 9.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Improving the gastrointestinal tolerability of aspirin in older people.

Authors:  Julia L Newton
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.